Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06926894 · ClinicalTrials.gov registry record · Phase 1
R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
A Phase 1 study of Cytomegalovirus Infections and BK Virus Infection, sponsored by Columbia University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT06926894: Recruiting Phase 1 study of Cytomegalovirus Infections and BK Virus Infection, sponsored by Columbia University.
NCT06926894 is a Phase 1 study of Cytomegalovirus Infections and BK Virus Infection that is actively recruiting participants, run by Columbia University. The registered enrollment target is 18 participants, below the 202-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06926894, a Phase 1 study of Cytomegalovirus Infections and BK Virus Infection, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective is to determine the safety and feasibility of administering R-MVST cells to patients with refractory viral reactivation and/or symptomatic disease caused by Epstein Barr Virus (EBV), cytomegalovirus (CMV), adenovirus (ADV) or BK virus. R-MVST cells will be generated on-demand from the closest partially human leukocyte antigen (HLA)-matched (minimum haploidentical) healthy donors or from the original allo-transplant donor if available. The investigator will closely monitor the recipients for potential toxicities including graft-versus-host disease (GVHD) post-infusion. Secondary objectives are to determine the effect of R-MVST infusion on viral load, possible recovery of antiviral immunity post-infusion and for evidence of clinical responses and overall survival. Recipients will be monitored for secondary graft failure at day 28 post R-MVST infusion.
Primary Outcome
This is to measure the incidence of toxicity post-infusion. Toxicities to consider include: GI toxicity, renal toxicity, hemorrhagic toxicity, cardiovascular toxicity hypotension, cardiac arrhythmia and left ventricular systolic dysfunction), neurological toxicity (somnolence and seizure), coagulation toxicity, vascular toxicity and pulmonary toxicity.
Conditions Studied
Interventions
- DRUG Rapidly generated virus specific T (R-MVST) cells
Study Locations (1)
New York
- Columbia University Medical Center / New-York Presbyterian - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2025-04-20 |
| Est. Completion | 2030-12 |
| Phase | Phase 1 |
What NCT06926894 shows while recruiting
NCT06926894 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 202-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (91% lower).
The record links to 5 conditions, with Cytomegalovirus Infections appearing as the primary indexed condition, and to 1 intervention - of which Rapidly generated virus specific T (R-MVST) cells is the first listed.
NCT06926894 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06926894 about?
NCT06926894 is a clinical study titled "R-MVST Cells for Treatment of Viral Infections in Children and Young Adults". The primary objective is to determine the safety and feasibility of administering R-MVST cells to patients with refractory viral reactivation and/or symptomatic disease caused by Epstein Barr Virus (EBV), cytomegalovirus (CMV), adenovirus (ADV) or BK virus. R-MVST cells will be generated on-demand f...
What is the current status of trial NCT06926894?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2025-04-20. Estimated completion is 2030-12.
What conditions does trial NCT06926894 study?
This clinical trial studies the following conditions: Cytomegalovirus Infections, BK Virus Infection, Immune Deficiency, Adenovirus, Epstein-Barr Virus.
What interventions are being tested in trial NCT06926894?
The interventions under investigation include: Rapidly generated virus specific T (R-MVST) cells (DRUG).
Who is sponsoring clinical trial NCT06926894?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06926894 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cytomegalovirus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06926894's enrollment target sits among peer trials
18 25th of 24 the lowest of 24 other Cytomegalovirus Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cytomegalovirus Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
R-MVST Cells for Treatment of Viral Infections
RECRUITING · Phase 1
-
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
RECRUITING · Phase 1
-
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation
ACTIVE NOT RECRUITING · Phase 1
-
Viral Specific T-Lymphocytes to Treat Adenovirus or CMV
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults
COMPLETED · Phase 1
-
A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI